O	0	12	Relationship
O	13	15	of
O	16	22	ZNF423
O	23	26	and
O	27	31	CTSO
O	32	36	with
O	37	43	breast
O	44	50	cancer
O	51	55	risk
O	56	58	in
O	59	62	two
O	63	73	randomised
B-intervention	74	83	tamoxifen
O	84	94	prevention
O	95	101	trials
O	101	102	.

O	103	104	A
O	105	109	case
O	109	110	-
O	110	117	control
O	118	123	study
O	124	128	from
O	129	132	two
O	133	143	randomised
O	144	150	breast
O	151	157	cancer
O	158	168	prevention
O	169	175	trials
O	176	178	of
O	179	188	tamoxifen
O	189	192	and
O	193	203	raloxifene
O	204	205	(
O	205	206	P
O	206	207	-
O	207	208	1
O	209	212	and
O	213	214	P
O	214	215	-
O	215	216	2
O	216	217	)
O	218	228	identified
O	229	235	single
O	235	236	-
O	236	246	nucleotide
O	247	260	polymorphisms
O	261	262	(
O	262	266	SNPs
O	266	267	)
O	268	270	in
O	271	273	or
O	274	278	near
O	279	284	genes
O	285	291	ZNF423
O	292	295	and
O	296	300	CTSO
O	301	303	as
O	304	311	factors
O	312	317	which
O	318	325	predict
O	326	331	which
O	332	337	women
O	338	342	will
O	343	349	derive
O	350	354	most
O	355	359	anti
O	359	360	-
O	360	366	cancer
O	367	374	benefit
O	375	379	from
O	380	389	selective
O	390	399	oestrogen
O	400	408	receptor
O	409	418	modulator
O	419	420	(
O	420	424	SERM
O	424	425	)
O	426	433	therapy
O	433	434	.

O	435	437	In
O	438	442	this
O	443	450	article
O	450	451	,
O	452	454	we
O	455	462	further
O	463	470	examine
O	471	475	this
O	476	484	question
O	485	490	using
O	491	496	blood
O	497	504	samples
O	505	509	from
O	510	513	two
O	514	524	randomised
O	525	534	tamoxifen
O	535	545	prevention
O	546	552	trials
O	552	553	:
O	554	557	the
O	558	571	International
O	572	578	Breast
O	579	585	Cancer
O	586	598	Intervention
O	599	604	Study
O	605	606	I
O	607	608	(
O	608	612	IBIS
O	612	613	-
O	613	614	I
O	614	615	)
O	616	619	and
O	620	623	the
O	624	629	Royal
O	630	637	Marsden
O	638	643	trial
O	644	645	(
O	645	652	Marsden
O	652	653	)
O	653	654	.

O	655	656	A
O	657	663	nested
O	664	668	case
O	668	669	-
O	669	676	control
O	677	682	study
O	683	686	was
O	687	695	designed
O	696	700	with
O	701	702	2
O	702	703	:
O	703	704	1
O	705	713	matching
O	714	716	in
O	717	721	IBIS
O	721	722	-
O	722	723	I
O	724	727	and
O	728	729	1
O	729	730	:
O	730	731	1
O	732	740	matching
O	741	743	in
O	744	751	Marsden
O	751	752	.

O	753	756	The
O	757	766	OncoArray
O	767	770	was
O	771	775	used
O	776	779	for
O	780	790	genotyping
O	791	794	and
O	795	803	included
O	804	807	two
O	808	812	SNPs
O	813	823	previously
O	824	834	identified
O	835	836	(
O	836	845	rs8060157
O	846	848	in
O	849	855	ZNF423
O	856	859	and
O	860	870	rs10030044
O	871	875	near
O	876	880	CTSO
O	880	881	)
O	881	882	,
O	883	886	and
O	887	890	102
O	891	898	further
O	899	903	SNPs
O	904	910	within
O	911	914	the
O	915	919	same
O	920	927	regions
O	927	928	.

O	929	936	Overall
O	936	937	,
O	938	943	there
O	944	948	were
B-intervention-participants	949	952	369
O	953	958	cases
O	959	962	and
B-control-participants	963	966	662
B-control	967	975	controls
O	975	976	,
O	977	981	with
B-intervention-participants	982	985	148
O	986	991	cases
O	992	995	and
B-control-participants	996	999	268
O	1000	1008	controls
O	1009	1013	from
O	1014	1017	the
O	1018	1027	tamoxifen
O	1028	1032	arms
O	1032	1033	.

O	1034	1038	Odds
O	1039	1045	ratios
O	1046	1050	were
O	1051	1060	estimated
O	1061	1063	by
O	1064	1075	conditional
O	1076	1084	logistic
O	1085	1095	regression
O	1095	1096	,
O	1097	1101	with
O	1102	1106	Wald
O	1107	1109	95
O	1110	1111	%
O	1112	1122	confidence
O	1123	1132	intervals
O	1132	1133	.

O	1134	1136	In
O	1137	1140	the
O	1141	1150	tamoxifen
O	1151	1155	arms
O	1155	1156	,
O	1157	1160	the
B-outcome	1161	1164	per
I-outcome	1164	1165	-
I-outcome	1165	1171	allele
I-outcome	1172	1176	odds
I-outcome	1177	1182	ratio
O	1183	1186	for
O	1187	1196	rs8060157
O	1197	1200	was
O	1201	1202	0
O	1202	1203	.
O	1203	1205	99
O	1206	1207	(
O	1207	1209	95
O	1210	1211	%
O	1211	1213	CI
O	1214	1215	0
O	1215	1216	.
O	1216	1218	73
O	1218	1219	-
O	1219	1220	1
O	1220	1221	.
O	1221	1223	34
O	1223	1224	)
O	1225	1228	and
O	1229	1230	1
O	1230	1231	.
O	1231	1233	00
O	1234	1235	(
O	1235	1237	95
O	1238	1239	%
O	1239	1241	CI
O	1242	1243	0
O	1243	1244	.
O	1244	1246	76
O	1246	1247	-
O	1247	1248	1
O	1248	1249	.
O	1249	1251	33
O	1251	1252	)
O	1253	1256	for
B-outcome	1257	1267	rs10030044
O	1267	1268	.

O	1269	1271	In
O	1272	1275	the
O	1276	1283	placebo
O	1284	1287	arm
O	1287	1288	,
O	1289	1292	the
O	1293	1297	odds
O	1298	1303	ratio
O	1304	1307	was
O	1308	1309	1
O	1309	1310	.
O	1310	1312	10
O	1313	1314	(
O	1314	1316	95
O	1317	1318	%
O	1318	1320	CI
O	1321	1322	0
O	1322	1323	.
O	1323	1325	87
O	1325	1326	-
O	1326	1327	1
O	1327	1328	.
O	1328	1330	40
O	1330	1331	)
O	1332	1335	for
B-outcome	1336	1345	rs8060157
O	1346	1349	and
O	1350	1351	1
O	1351	1352	.
O	1352	1354	01
O	1355	1356	(
O	1356	1358	95
O	1359	1360	%
O	1360	1362	CI
O	1363	1364	0
O	1364	1365	.
O	1365	1367	79
O	1367	1368	-
O	1368	1369	1
O	1369	1370	.
O	1370	1372	29
O	1372	1373	)
O	1374	1377	for
B-outcome	1378	1388	rs10030044
O	1388	1389	.

O	1390	1395	There
O	1396	1399	was
O	1400	1402	no
O	1403	1411	evidence
O	1412	1414	to
O	1415	1422	suggest
O	1423	1427	that
O	1428	1433	other
O	1434	1438	SNPs
O	1439	1441	in
O	1442	1445	the
O	1446	1457	surrounding
O	1458	1465	regions
O	1466	1468	of
O	1469	1474	these
O	1475	1479	SNPs
O	1480	1485	might
O	1486	1493	predict
O	1494	1502	response
O	1503	1505	to
O	1506	1515	tamoxifen
O	1515	1516	.

O	1517	1524	Results
O	1525	1529	from
O	1530	1535	these
O	1536	1539	two
O	1540	1550	prevention
O	1551	1557	trials
O	1558	1560	do
O	1561	1564	not
O	1565	1572	support
O	1573	1576	the
O	1577	1584	earlier
O	1585	1593	findings
O	1593	1594	.

O	1595	1604	rs8060157
O	1605	1607	in
O	1608	1614	ZNF423
O	1615	1618	and
O	1619	1629	rs10030044
O	1630	1634	near
O	1635	1639	CTSO
O	1640	1642	do
O	1643	1646	not
O	1647	1653	appear
O	1654	1656	to
O	1657	1664	predict
O	1665	1673	response
O	1674	1676	to
O	1677	1686	tamoxifen
O	1686	1687	.
